Field diagnosis of tree diseases has traditionally meant collecting samples, shipping them to a lab, and waiting days or weeks for results. By the time you get confirmation, the pathogen might have spread significantly. Rapid diagnostic kits are changing this timeline from weeks to minutes.

How the Technology Works

Most rapid diagnostic kits use immunochromatography, the same basic technology as a home pregnancy test. A sample of plant tissue, bark, or soil is processed with a buffer solution that releases pathogen proteins or DNA. This solution flows across a test strip containing antibodies or nucleic acid probes specific to the target pathogen.

If the target is present, binding occurs at a test line on the strip, creating a visible colour change. It’s binary – positive or negative – with results typically appearing within 10-15 minutes. No specialized equipment, no laboratory, just a test strip and some basic sample preparation.

The technology isn’t new, but developing tests that work reliably with plant samples in field conditions has taken years of refinement. Plants contain compounds that can interfere with the tests, and environmental conditions affect both sample quality and test performance.

What Can Be Detected

Phytophthora species are among the best-established targets for rapid tests. Several commercial kits can detect Phytophthora cinnamomi, the pathogen responsible for dieback in Australian native forests, directly from soil or root samples. Other kits target specific Phytophthora species that affect plantation forests or nursery stock.

Myrtle rust (Austropuccinia psidii) is another key target. Rapid tests can confirm the fungus from leaf samples showing early symptoms, allowing immediate decisions about containment measures rather than waiting for microscopic identification or genetic confirmation.

Dutch elm disease, sudden oak death, and various root rot pathogens all have rapid tests available or in development. The range of detectable pathogens expands every year as researchers develop new antibody and DNA probe sets.

Field Applications

Border inspection is an obvious application. When a quarantine officer finds suspicious symptoms on imported plants or packaging material, immediate testing provides faster decisions about whether goods can be released or need treatment. This matters enormously for perishable products where delays are costly.

In forest surveillance programs, rapid tests let field crews cover more ground effectively. Instead of collecting dozens of samples for lab testing, crews can test on site and only collect samples from positive results for confirmation and further analysis. This multiplies the number of sites that can be monitored with the same resources.

Response to disease reports benefits hugely from rapid testing. When a landholder reports dying trees, getting a quick diagnosis determines whether it’s a notifiable pathogen requiring regulatory response or a less serious issue. The difference between moving crews and equipment within hours versus days can be critical for containment.

Limitations and Challenges

Sensitivity is the main limitation. Rapid tests generally can’t detect pathogens at the same low concentrations that laboratory methods can. This means early infections might give false negatives, and negative results often need confirmation with more sensitive tests.

Specificity varies between tests. Some are highly specific to a single pathogen species, while others cross-react with related organisms. A positive result might mean “Phytophthora detected” without saying which species, requiring follow-up identification.

Sample quality matters enormously. Field conditions aren’t controlled laboratory environments. Samples might be contaminated, degraded, or simply not contain enough pathogen material. User technique affects results – proper sample collection and preparation require training and practice.

Environmental conditions affect test performance. Extreme temperatures, humidity, and sunlight exposure can all compromise results. Tests need to be stored properly and used within their shelf life, which isn’t always easy in field vehicles bouncing around remote forests.

Cost Considerations

Individual tests typically cost between $15 and $50, which sounds expensive until you compare it to the cost of laboratory PCR testing ($80-150) plus shipping and the value of faster decisions. For routine surveillance where most samples are negative, the costs add up either way.

The economic calculation depends on the specific application. In high-risk situations where rapid decision-making prevents significant damage, the per-test cost is trivial. For routine screening where prevalence is low, the costs can become significant across hundreds of tests.

Some organizations have developed internal testing systems using LAMP (Loop-Mediated Isothermal Amplification) technology that provides lab-quality sensitivity in a portable format. These require more equipment and technical skill than immunochromatographic strips but dramatically reduce per-sample costs for high-volume testing.

The Human Factor

Rapid tests don’t eliminate the need for expertise. Interpreting results requires understanding what the test does and doesn’t detect, recognizing when symptoms don’t match test results, and knowing when follow-up testing is needed.

There’s a risk that positive results get treated as definitive when they should trigger further investigation. Equally, negative results might provide false reassurance if the test wasn’t appropriate for the situation or sample quality was poor.

Training field staff to use tests effectively is an ongoing process. It’s not just about following the kit instructions but understanding the underlying biology, recognizing sampling artefacts, and maintaining proper quality control procedures.

Team400 has worked with some biosecurity agencies on decision support systems that guide field officers through the testing process, helping ensure appropriate test selection and interpretation. Getting the human-technology interface right matters as much as the test chemistry itself.

Future Development

Next-generation rapid tests are moving toward multiplexing – detecting multiple pathogens simultaneously from a single sample. This is particularly valuable for situations where symptoms could be caused by several different organisms and testing for each separately is impractical.

Quantitative tests that provide information about pathogen load, not just presence/absence, are emerging. Knowing whether a sample contains a few propagules or massive infection levels helps assess risk and inform management decisions.

Integration with smartphone technology for result recording, GPS tagging, and immediate data transmission is becoming standard. This turns each field test into a data point in a larger surveillance network, enabling real-time mapping of disease distribution.

CRISPR-based diagnostic systems are being adapted for field use, potentially offering laboratory-level sensitivity in portable formats. These are still largely experimental but show real promise for situations where detecting very low pathogen levels is critical.

Rapid diagnostic kits aren’t replacing laboratory analysis, but they’re changing the workflow. First response can now include on-site diagnosis, with laboratory testing focused on confirmation, detailed characterization, and cases where rapid tests are inconclusive. That shift is making biosecurity surveillance faster and more effective, which ultimately means better protection for Australia’s forests.